NEW YORK (GenomeWeb) – Twelve years after its founding, Germany-based rare hereditary disease diagnostics firm Centogene is preparing to expand into the US as it awaits clearance from the US Food and Drug Administration for its diagnostic tool for generating reports on clinical variants.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.